NEUBERGER HIGH YIELD STRATEGIES FUND ANNOUNCES PRELIMINARY RESULTS OF RIGHTS OFFERING

Rhea-AI Summary

Neuberger High Yield Strategies Fund (NYSE American: NHS) announced preliminary results of its transferable rights offering that ran March 23, 2026–April 15, 2026. The final subscription price was $6.50 per share, equal to 92.5% of NAV at the close on the expiration date.

The Offer was over-subscribed and is expected to issue approximately 10,463,948 shares, generating about $68.0 million gross proceeds. Shares will be issued after pro rata allocation and receipt of payments; final results will be announced later.

Positive

• Gross proceeds of approximately $68.0 million
• Issuance of approximately 10,463,948 shares
• Subscription price set at 92.5% of NAV (discount)

Negative

• Share issuance will dilute existing shareholders
• Subscription price at a 7.5% discount to NAV

News Market Reaction – NHS

+0.15%

+0.15% Session close to close

In the Apr 16 session, NHS gained 0.15%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details preliminary results of NHS’s transferable rights offering, including a fin...

Analysis

This announcement details preliminary results of NHS’s transferable rights offering, including a final subscription price of $6.50, set at 92.5% of NAV, and expected issuance of about 10,463,948 shares for roughly $68.0 million in gross proceeds. It follows the March launch of the same rights issue. Investors may track final offering results, impacts on total shares outstanding, and how the added capital interacts with the fund’s ongoing distribution policy.

Key Figures

Final subscription price: $6.50 per share NAV pricing floor: 92.5% of NAV Rights ratio: 3 Rights for 1 share +5 more

8 metrics

Final subscription price $6.50 per share Rights offering subscription price set at 92.5% of NAV

NAV pricing floor 92.5% of NAV Subscription price set as 92.5% of NAV on Expiration Date

Rights ratio 3 Rights for 1 share Holders submit three Rights plus cash to purchase one share

Rights distribution 1 Right per share One transferable Right issued for each common share held

New shares issued 10,463,948 shares Approximate number of new common shares from the Offer

Gross proceeds $68.0 million Expected gross proceeds from the rights offering

Record date March 23, 2026 Stockholders of record received Rights as of this date

Expiration Date April 15, 2026 Rights offering expired on this date

Previous Offering Reports

1 past event · Latest: Mar 12 (Negative)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 12	Rights offering launch	Negative	-3.7%	Announced discounted transferable rights offering with 1-for-3 subscription structure.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior rights-offering news in March 2026 led to a negative price reaction, suggesting investors have treated this type of dilution-related event cautiously.

Recent Company History

Over the past several months, NHS has focused on income stability and capital-raising. Multiple monthly distribution declarations at $0.0905 per share underscored its level distribution policy, while the March 12, 2026 announcement introduced the transferable rights offering now reaching preliminary completion. That earlier offering news saw a -3.73% move, indicating sensitivity to dilution. Today’s preliminary, over-subscribed results follow through on that capital-raising plan.

Key Terms

transferable rights offering, net asset value, prospectus

3 terms

transferable rights offering financial

"announced today the preliminary results of its transferable rights offering (the "Offer")"

A transferable rights offering is a company raising money by giving existing shareholders tradable tokens called “rights” that let them buy new shares at a set price. Think of it like a coupon that shareholders can either use to buy discounted stock, sell to someone else, or let expire; it matters to investors because exercising preserves ownership percentage while selling can provide cash, and the overall offering can dilute share value for those who do nothing.

net asset value financial

"equal to 92.5% of the Fund's net asset value per share of Common Stock"

Net asset value is the total value of an investment fund's assets minus any liabilities, divided by the number of shares or units outstanding. It represents the per-share worth of the fund, similar to how the value of a house is determined by its total worth after debts are subtracted. Investors use it to gauge the true value of their holdings and to compare different investment options.

View in glossary

prospectus regulatory

"This document is not an offering, which can only be made by a prospectus."

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, April 16, 2026 /PRNewswire/ -- Neuberger High Yield Strategies Fund Inc. (NYSE American: NHS) (the "Fund") has announced today the preliminary results of its transferable rights offering (the "Offer"), which commenced on March 23, 2026 and expired on April 15, 2026 (the "Expiration Date").

Pursuant to the Offer, the Fund issued one transferable right (a "Right") for each share of common stock of the Fund ("Common Stock") held by stockholders of record as of March 23, 2026. Holders of Rights were entitled to purchase Common Stock by submitting three Rights and the subscription price per share for each share purchased. In accordance with the terms of the Offer, the final subscription price of $6.50 per share of Common Stock was equal to 92.5% of the Fund's net asset value per share of Common Stock at the close of trading on the NYSE American on the Expiration Date.

Based on the preliminary results, the Offer was over-subscribed. The Offer is expected to result in the issuance of approximately 10,463,948 shares of Common Stock and the gross proceeds of the Offer are expected to be approximately $68.0 million. The shares of Common Stock subscribed for will be issued promptly after completion of the pro rata allocation of the over-subscription shares and receipt of all stockholder payments. The Fund will return to subscribing investors the full amount of any excess payments. The final results of the Offer will be announced at a later date.

The information in this press release is not complete and is subject to change. This document is not an offer to sell any securities and is not soliciting an offer to buy any securities in any jurisdiction where the offer or sale is not permitted. This document is not an offering, which can only be made by a prospectus. Investors should consider the Fund's investment objective, risks, charges and expenses carefully before investing. Copies of the Fund's prospectus supplement and accompanying prospectus and other documents the Fund has filed with the Securities and Exchange Commission may be obtained by visiting the EDGAR database on the SEC's website at www.sec.gov.

Inquiries regarding the Offer should be directed to the Fund's Information Agent, EQ Fund Solutions, LLC, at (800) 290-6428.

About Neuberger High Yield Strategies Fund Inc. The Fund's investment objective is to seek high total return (income plus capital appreciation). Under normal market conditions, the Fund invests at least 80% of its total assets in high yield debt (below investment grade) securities of U.S. and foreign issuers. The Fund may invest up to 20% of its total assets in other securities and financial instruments, and up to 15% of its total assets in collateralized loan obligations.

About Neuberger

Neuberger is an employee-owned, private, independent investment manager founded in 1939 with approximately 3,000 employees across 26 countries. The firm manages $567 billion of equities, fixed income, private markets, real estate and hedge fund portfolios for global institutions, advisors and individuals. Neuberger's investment philosophy is founded on active management, fundamental research and engaged ownership. The firm is proud to be recognized for its commitment to its two constituents, clients and employees. Again in 2025, we were named Best Asset Manager for Institutional Investors in the US (Crisil Coalition Greenwich) and the #1 Best Place to Work in Money Management (Pensions & Investments, firms with more than 1,000 employees). Neuberger has no corporate parent or unaffiliated external shareholders. Visit www.nb.com for more information, including www.nb.com/disclosure-global-communications for information on awards. Data as of March 31, 2026.

Contact:
Neuberger Berman Investment Advisers LLC                                         
Investor Information
(877) 461-1899

View original content to download multimedia:https://www.prnewswire.com/news-releases/neuberger-high-yield-strategies-fund-announces-preliminary-results-of-rights-offering-302743938.html

SOURCE Neuberger Berman

FAQ

What were the results of NHS's rights offering that expired April 15, 2026?

The Offer was over-subscribed and is expected to issue about 10,463,948 shares. According to the company, gross proceeds are expected to be approximately $68.0 million, with final allocation and issuance pending.

What was the subscription price and how did it relate to NHS NAV on April 15, 2026?

The final subscription price was $6.50 per share, equal to 92.5% of NAV. According to the company, that represents a 7.5% discount to the Fund's net asset value at the close.

How many rights were required to buy one NHS share in the March–April 2026 offering?

Holders needed to submit three Rights to purchase one share of common stock. According to the company, one Right was issued per share held of record as of March 23, 2026.

Will NHS return excess payments from the over-subscribed rights offering?

Yes. According to the company, the Fund will return the full amount of any excess payments to subscribing investors after pro rata allocation and processing of subscriptions.

When will NHS announce the final results and issue the subscribed shares?

The final results will be announced at a later date and shares will be issued promptly after pro rata allocation. According to the company, issuance follows receipt of all stockholder payments.